Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... Consider more frequent monitoring for patients with a history of liver disease or elevated liver function tests (LFTs) at baseline.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the ...

Concierge medicine experts Specialdocs Consultants broadened its footprint considerably in 2024, welcoming a record 26 new physician clients to its rapidly growing national network of outstanding ...

It later moved into medicines, commercialising aspirin around the turn of the 20th century, one of the most successful pharmaceuticals ... And firms such as Vertex have added to the controversy ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...